This gene encodes the enzyme responsible for pre-mRNA editing of the glutamate receptor subunit B by site-specific deamination of adenosines. Studies in rats found that this enzyme acted on its own pre-mRNA molecules to convert an AA dinucleotide to an AI dinucleotide which resulted in a new splice site. Alternative splicing of this gene results in several transcript variants, some of which have been characterized by the presence or absence of an ALU cassette insert and a short or long C-terminal region.[3]
ADARB1 (ADAR2) requires the small molecule inositol hexakisphosphate (IP6) for proper function.[4] ADAR2 is an A-to-I RNA-editing enzyme that mostly acts on protein-coding substrates.[5]
References
↑Mittaz L, Scott HS, Rossier C, Seeburg PH, Higuchi M, Antonarakis SE (April 1997). "Cloning of a human RNA editing deaminase (ADARB1) of glutamate receptors that maps to chromosome 21q22.3". Genomics. 41 (2): 210–7. doi:10.1006/geno.1997.4655. PMID9143496.
Valenzuela A, Blanco J, Callebaut C, Jacotot E, Lluis C, Hovanessian AG, Franco R (1997). "HIV-1 envelope gp120 and viral particles block adenosine deaminase binding to human CD26". Advances in Experimental Medicine and Biology. 421: 185–92. doi:10.1007/978-1-4757-9613-1_24. PMID9330696.
Melcher T, Maas S, Herb A, Sprengel R, Seeburg PH, Higuchi M (February 1996). "A mammalian RNA editing enzyme". Nature. 379 (6564): 460–4. doi:10.1038/379460a0. PMID8559253.
O'Connell MA, Gerber A, Keller W (January 1997). "Purification of human double-stranded RNA-specific editase 1 (hRED1) involved in editing of brain glutamate receptor B pre-mRNA". The Journal of Biological Chemistry. 272 (1): 473–8. doi:10.1074/jbc.272.1.473. PMID8995285.
Valenzuela A, Blanco J, Callebaut C, Jacotot E, Lluis C, Hovanessian AG, Franco R (April 1997). "Adenosine deaminase binding to human CD26 is inhibited by HIV-1 envelope glycoprotein gp120 and viral particles". Journal of Immunology. 158 (8): 3721–9. PMID9103436.
Villard L, Tassone F, Haymowicz M, Welborn R, Gardiner K (March 1997). "Map location, genomic organization and expression patterns of the human RED1 RNA editase". Somatic Cell and Molecular Genetics. 23 (2): 135–45. doi:10.1007/BF02679972. PMID9330641.
Blanco J, Valenzuela A, Herrera C, Lluís C, Hovanessian AG, Franco R (July 2000). "The HIV-1 gp120 inhibits the binding of adenosine deaminase to CD26 by a mechanism modulated by CD4 and CXCR4 expression". FEBS Letters. 477 (1–2): 123–8. doi:10.1016/S0014-5793(00)01751-8. PMID10899322.
Herrera C, Morimoto C, Blanco J, Mallol J, Arenzana F, Lluis C, Franco R (June 2001). "Comodulation of CXCR4 and CD26 in human lymphocytes". The Journal of Biological Chemistry. 276 (22): 19532–9. doi:10.1074/jbc.M004586200. PMID11278278.
Jaikaran DC, Collins CH, MacMillan AM (October 2002). "Adenosine to inosine editing by ADAR2 requires formation of a ternary complex on the GluR-B R/G site". The Journal of Biological Chemistry. 277 (40): 37624–9. doi:10.1074/jbc.M204126200. PMID12163487.
Slavov D, Gardiner K (October 2002). "Phylogenetic comparison of the pre-mRNA adenosine deaminase ADAR2 genes and transcripts: conservation and diversity in editing site sequence and alternative splicing patterns". Gene. 299 (1–2): 83–94. doi:10.1016/S0378-1119(02)01016-8. PMID12459255.